Actuarial overall survival curves for patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Actuarial overall survival in patients with MPM treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was significantly shorter in male versus female patients (graph A), patients 60 years or older versus younger (graph B), patients with high versus low histologic grade tumors (graph C), and patients with suboptimal (CC-2+CC-3*) versus optimal (CC-0+CC-1*) completeness of surgical cytoreduction scores (graph D). All p-values are 0.02.

* Completeness of surgical cytoreduction score defined as:
CC-0: No visible evidence of residual disease
CC-1: Residual tumor <2.5 mm
CC-2: Residual tumor 2.5 to 25mm
CC-3: Residual tumor >25 mm or confluent tumor nodules

Reproduced from: Alexander HR Jr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 2013; 153:779. Illustration used with the permission of Elsevier Inc. All rights reserved.

Graphic 95961 Version 1.0

خرید پکیج

Actuarial overall survival curves for patients with malignant peritoneal mesothelioma (MPM) treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy